Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 9/20 | 0.70 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | USP2 | O75604 | 1/20 | 0.59 |
| ▸ | CCR2 | P41597 | 1/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | NCF1 | P14598 | 1/20 | 0.55 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.55 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.53 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.53 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL151230 | 1.00 | HRH3 (0.70) | HRH3HRH4ALDH1A1KDM4EUSP2 | |
| SCHEMBL150808 | 0.98 | HRH3 (0.68) | HRH3HRH4ALDH1A1KDM4EUSP2 | |
| SCHEMBL27895178 | 0.94 | CCR2 (0.64) | HRH3HRH4ALDH1A1KDM4EUSP2 | |
| SCHEMBL20804360 | 0.90 | KCNJ1 (0.66) | HRH3ALDH1A1USP2CCR2CYP2D6 | |
| SCHEMBL28024576 | 0.90 | KCNJ1 (0.66) | HRH3ALDH1A1USP2CCR2CYP2D6 | |
| SCHEMBL22205089 | 0.88 | NCF1 (0.60) | HRH3HRH4ALDH1A1KDM4EUSP2 | |
| Hydrochloric Acid SCHEMBL29521642 | 0.87 | NCF1 (0.58) | HRH3HRH4USP2CCR2CYP2D6 | |
| SCHEMBL5026453 | 0.85 | CXCR4 (0.69) | HRH3HRH4USP2CCR2CYP2D6 | |
| SCHEMBL6765479 | 0.84 | CXCR4 (0.73) | HRH3USP2CCR2CYP2D6TSHR | |
| SCHEMBL4277270 | 0.83 | HRH3 (1.00) | HRH3HRH4ALDH1A1KDM4ECYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022197877-A1 | METHODS AND COMPOSITIONS FOR TIME DELAYED BIO-ORTHOGONAL RELEASE OF CYTOTOXIC AGENTS | GENENTECH, INC. (US) | 2022-09-22 | — | — | WO | disclosed |
| EP-2822656-B1 | 3-ARYL-5-SUBSTITUTED-ISOQUINOLIN-1-ONE COMPOUNDS AND THEIR THERAPEUTIC USE | CANCER RES INST ROYAL (GB) | 2016-10-19 | — | — | EP | disclosed |
| US-9469710-B2 | Polymers functionalized with nitrile compounds containing a protected amino group | BRIDGESTONE CORPORATION (JP) | 2016-10-18 | — | — | US | disclosed |
| US-9193689-B2 | 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2015-11-24 | — | — | US | disclosed |
| CN-103333275-B | With the polymkeric substance of functionalized with nitrile compounds comprising protected amino | BRIDGESTONE CO., LTD. (JP) | 2015-07-29 | — | — | CN | disclosed |
| US-20150148489-A1 | POLYMERS FUNCTIONALIZED WITH NITRILE COMPOUNDS CONTAINING A PROTECTED AMINO GROUP | BRIDGESTONE CORPORATION (JP) | 2015-05-28 | — | — | US | disclosed |
| US-20150099732-A1 | 3-ARYL-5-SUBSTITUTED-ISOQUINOLIN-1-ONE COMPOUNDS AND THEIR THERAPEUTIC USE | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2015-04-09 | — | — | US | disclosed |
| US-8735494-B2 | Polymers functionalized with nitrile compounds containing a protected amino group | BRIDGESTONE CORPORATION (JP) | 2014-05-27 | — | — | US | disclosed |
| US-8680091-B2 | 6-arylalkylamino-2,3,4,5-tetrahydro-1H-benzo[d]azepines as 5-HT2C receptor agonists | ELI LILLY AND COMPANY (US) | 2014-03-25 | — | — | US | disclosed |
| US-8680091-B2 | 6-arylalkylamino-2,3,4,5-tetrahydro-1H-benzo[d]azepines as 5-HT2C receptor agonists | ELI LILLY AND COMPANY (US) | 2014-03-25 | — | — | US | disclosed |
| WO-2011091346-A2 | POLYMERS FUNCTIONALIZED WITH NITRILE COMPOUNDS CONTAINING A PROTECTED AMINO GROUP | BRIDGESTONE CORPORATION (JP) | 2011-07-28 | — | — | WO | disclosed |
| US-20080269196-A1 | 6-Arylalkylamino-2,3,4,5-Tetrahydro-1H-Benzo[D]Azepines as 5-Ht2c Receptor Agonists | ELI LILLY AND COMPANY | 2008-10-30 | — | — | US | disclosed |
| US-20080269196-A1 | 6-Arylalkylamino-2,3,4,5-Tetrahydro-1H-Benzo[D]Azepines as 5-Ht2c Receptor Agonists | ELI LILLY AND COMPANY | 2008-10-30 | — | — | US | disclosed |
| US-20080269196-A1 | 6-Arylalkylamino-2,3,4,5-Tetrahydro-1H-Benzo[D]Azepines as 5-Ht2c Receptor Agonists | ELI LILLY AND COMPANY | 2008-10-30 | — | — | US | disclosed |
| CN-101258131-A | As 5-HT2c6-aralkylamino-2, 3,4, 5-tetrahydro-1H-benzo [ d ] receptors as agonists]Aza * | LILLY CO ELI (US) | 2008-09-03 | — | — | CN | disclosed |
| EP-1924561-A2 | 6-ARYLALKYLAMINO- 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | Eli Lilly & Company (US) | 2008-05-28 | — | — | EP | disclosed |
| WO-2007028083-A2 | 6-ARYLALKYLAMINO- 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2007-03-08 | — | — | WO | disclosed |
| WO-2007028083-A2 | 6-ARYLALKYLAMINO- 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2007-03-08 | — | — | WO | disclosed |
| US-4154928-A | Substituted isoxazolo compounds | SANDOZ, INC. (US) | 1979-05-15 | — | — | US | disclosed |
| US-4113727-A | Process for the preparation of substituted isoxazolo[4,5-c]pyridin-4-(5H)-ones | SANDOZ, INC. (US) | 1978-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150099732-A1 | 3-ARYL-5-SUBSTITUTED-ISOQUINOLIN-1-ONE COMPOUNDS AND THEIR THERAPEUTIC USE | TNKS, TNKS2, PARP11 | HRH3 3405/4885HRH4 4440/4885ALDH1A1 1976/4885 |
| US-20080269196-A1 | 6-Arylalkylamino-2,3,4,5-Tetrahydro-1H-Benzo[D]Azepines as 5-Ht2c Receptor Agonists | HTR2C, HTR1A, HTR2A | HRH3 394/4885HRH4 201/4885ALDH1A1 397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.